GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    20-49
Key business

You may also be interested in